Literature DB >> 29949168

Relationship of platelet microparticle CD62P and activated GP IIb/IIIa with hypercoagulable state after atrial fibrillation radiofrequency catheter ablation.

X-Z Zhang1, A-G Liu, M-L Guo, J Guan, S-L Cai, Q Du, C-Y Zhou.   

Abstract

OBJECTIVE: The morbidity of atrial fibrillation (AF) is 1%-2% in clinic. Radiofrequency catheter ablation (RFCA) is a type of radical interventional therapy for AF, whereas it may lead to a hypercoagulable state. This study evaluated platelet particle CD62P and platelet activation biomarker GP IIb/IIIa expressions in AF patients treated by RFCA, and aimed to analyze their relationships with the hypercoagulable state after RFCA. PATIENTS AND METHODS: A total of 60 AF patients received RFCA in our hospital were enrolled. The patients were divided into group A as hypercoagulable state group and group B as non-hypercoagulable group. Healthy volunteers were selected as normal control. Serum D-Dimer, parathyroid activity index 1 (PAI-1), and tissue plasminogen activator (t-PA) content were tested by using enzyme-linked immunosorbent assay (ELISA), while peripheral CD62P and GP IIb/IIIa expressions were detected by using flow cytometry before, after, and seven days after RFCA.
RESULTS: D-Dimer and PAI-1 levels increased, while t-PA reduced in group A compared with that in group B and control (p<0.05). D-Dimer and t-PA contents gradually elevated, whereas t-PA level gradually declined in group A before, after, and seven days after RFCA (p<0.05). Serum CD62P and GP IIb/IIIa expressions in group A were significantly higher compared to that in group B and control (p<0.05). CD62P and GP IIb/IIIa levels were significantly higher seven days after RFCA compared with immediate after RFCA in group A (p<0.05). CD62P showed a positive correlation with GP IIb/IIIa in hypercoagulable state patients after RFCA (p<0.05).
CONCLUSIONS: AF patient may appear in hypercoagulable state after RFCA. CD62P and GP IIb/IIIa significantly increased and exhibited a positive correlation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29949168     DOI: 10.26355/eurrev_201806_15277

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  Si-Miao-Yong-An Decoction Protects Against Cardiac Hypertrophy and Dysfunction by Inhibiting Platelet Aggregation and Activation.

Authors:  Congping Su; Qing Wang; Huimin Zhang; Wenchao Jiao; Hui Luo; Lin Li; Xiangyang Chen; Bin Liu; Xue Yu; Sen Li; Wei Wang; Shuzhen Guo
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

2.  ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-Cadherin after Insufficient Radiofrequency Ablation.

Authors:  Jian Kong; Changyu Yao; Shuying Dong; Shilun Wu; Yangkai Xu; Ke Li; Liang Ji; Qiang Shen; Qi Zhang; Rui Zhan; Hongtu Cui; Changping Zhou; Haigang Niu; Guoming Li; Wenbing Sun; Lemin Zheng
Journal:  Adv Sci (Weinh)       Date:  2021-01-04       Impact factor: 16.806

3.  Relationship of Platelet Glycoprotein IIb/IIIa and CD62P With Hypercoagulable State After Oncologic Surgery.

Authors:  Xin Zhong; Zhongze Cao; Jiayi Song; Yuanmeng Liu; Qiang Guo
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 4.  Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.